#United States #Cambrex #East Rutherford #API Production #US Drug Supply

Cambrex's Ambitious $120 Million Investment

In a notable move towards bolstering the U.S. pharmaceutical landscape, Cambrex, a leading contract development and manufacturing organization (CDMO), has unveiled plans for a substantial investment of $120 million. This funding is set to significantly enhance their API (Active Pharmaceutical Ingredient) production capabilities in the United States. The aim is twofold: to meet the soaring demand in API development and manufacturing and to reinforce the stability of the U.S. drug supply chain.

Responding to Rising Demands

The move comes amidst a shifting paradigm in pharmaceutical manufacturing. As outlined by Cambrex's CEO, Thomas Loewald, there is a clear trend where clients are collaborating with state and federal authorities to consolidate drug manufacturing domestically. The United States holds the title of the largest pharmaceutical market globally, making local API production crucial for ensuring supply chain security and resilience. Loewald emphasized that Cambrex will play a pivotal role in this transition, responding robustly to the increasing demand for partnership from clients eager to capitalize on the expanded capacity.

Expanding Production Capacity

This investment will enable Cambrex to increase the production capacity of its facility located in Charles City, Iowa, by 40%, reaching nearly one million liters. The Charles City site encompasses 45 acres and is known for manufacturing a wide array of active ingredients and pharmaceutical intermediates, including highly potent molecules and controlled substances. This enhancement not only positions Cambrex as a leader in the market but also ensures a steady supply of vital medications to meet the country’s healthcare needs.

Strengthening the U.S. Production Network

With an eye on the future, Cambrex is committed to supporting the long-term stability of pharmaceutical manufacturing in the United States. Loewald further stated that the investment reflects the company’s dedication to meeting evolving client needs, focusing on the production of small molecules and peptides. The announcement is part of Cambrex's ongoing strategy to reinforce its drug development and manufacturing network.

This recent investment builds upon Cambrex's track record of significant enhancements over the past five years, which includes:

• - 2022: Addition of highly potent actives and large-scale production capabilities at the Charles City site.
• - 2023: Opening of state-of-the-art laboratories along with clinical and commercial production capacities tailored for small- to mid-scale quantities for rare and orphan disease therapies in High Point, North Carolina.
• - 2025: Expansion of capacities and introduction of new GMP (Good Manufacturing Practices) production capabilities for peptide therapeutics in Waltham, Massachusetts.

These continuous advancements illustrate Cambrex’s unwavering commitment to innovating and scaling up capacity to address the growing needs of the pharmaceutical industry.

About Cambrex

Cambrex is renowned globally as a leading CDMO that offers integrated drug substance development and manufacturing services across the entire lifecycle of pharmaceuticals. With over 40 years of industry experience and a dedicated workforce of 2,000 professionals serving clients primarily in North America and Europe, Cambrex leverages a suite of specialized drug substance technologies. Their offerings include Continuous Flow, controlled substances, peptide synthesis, solid-state research, material characterization, and the production of highly potent APIs.

This bold investment by Cambrex not only fortifies their market position but also underscores their critical role in enhancing the pharmaceutical supply chain’s resilience and reliability in the U.S., where the demand for innovative therapies is continually rising.